WO2006084272A3 - Methods of predicting chemotherapy responsiveness in breast cancer patients - Google Patents

Methods of predicting chemotherapy responsiveness in breast cancer patients Download PDF

Info

Publication number
WO2006084272A3
WO2006084272A3 PCT/US2006/004280 US2006004280W WO2006084272A3 WO 2006084272 A3 WO2006084272 A3 WO 2006084272A3 US 2006004280 W US2006004280 W US 2006004280W WO 2006084272 A3 WO2006084272 A3 WO 2006084272A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
breast cancer
methods
cancer patients
predicting
Prior art date
Application number
PCT/US2006/004280
Other languages
French (fr)
Other versions
WO2006084272A2 (en
WO2006084272A9 (en
Inventor
Hongyue Dai
Stephen H Friend
Paul Deutsch
Original Assignee
Rosetta Inpharmatics Llc
Merck & Co Inc
Hongyue Dai
Stephen H Friend
Paul Deutsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Inpharmatics Llc, Merck & Co Inc, Hongyue Dai, Stephen H Friend, Paul Deutsch filed Critical Rosetta Inpharmatics Llc
Priority to EP06720440A priority Critical patent/EP1848825A2/en
Priority to JP2007554325A priority patent/JP2008536094A/en
Priority to CA002596640A priority patent/CA2596640A1/en
Publication of WO2006084272A2 publication Critical patent/WO2006084272A2/en
Publication of WO2006084272A9 publication Critical patent/WO2006084272A9/en
Publication of WO2006084272A3 publication Critical patent/WO2006084272A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a method of predicting the responsiveness of a breast cancer patient to chemotherapy based on the patient's cellular constituent profile comprising measurements of a plurality of cellular constituents in a sample derived from the patient, the patient's estrogen receptor level, and the patient's estrogen receptor level relative to the patient's age. The invention also provides a method for selecting patients for enrollment in a clinical trial of a drug for treating breast cancer based on these factors.
PCT/US2006/004280 2005-02-04 2006-02-06 Methods of predicting chemotherapy responsiveness in breast cancer patients WO2006084272A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06720440A EP1848825A2 (en) 2005-02-04 2006-02-06 Methods of predicting chemotherapy responsiveness in breast cancer patients
JP2007554325A JP2008536094A (en) 2005-02-04 2006-02-06 Methods for predicting chemotherapy responsiveness in breast cancer patients
CA002596640A CA2596640A1 (en) 2005-02-04 2006-02-06 Methods of predicting chemotherapy responsiveness in breast cancer patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65036505P 2005-02-04 2005-02-04
US60/650,365 2005-02-04

Publications (3)

Publication Number Publication Date
WO2006084272A2 WO2006084272A2 (en) 2006-08-10
WO2006084272A9 WO2006084272A9 (en) 2007-10-04
WO2006084272A3 true WO2006084272A3 (en) 2008-08-28

Family

ID=36778033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/004280 WO2006084272A2 (en) 2005-02-04 2006-02-06 Methods of predicting chemotherapy responsiveness in breast cancer patients

Country Status (4)

Country Link
EP (1) EP1848825A2 (en)
JP (1) JP2008536094A (en)
CA (1) CA2596640A1 (en)
WO (1) WO2006084272A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514209B2 (en) 2001-06-18 2009-04-07 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
CA2558808A1 (en) 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
WO2007136724A2 (en) 2006-05-17 2007-11-29 Cellumen, Inc. Method for automated tissue analysis
EP2044431B1 (en) 2006-07-17 2019-04-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Computer systems and methods for selecting subjects for clinical trials
EP3135773A1 (en) * 2006-09-27 2017-03-01 Sividon Diagnostics GmbH Methods for breast cancer prognosis
EP2162459B1 (en) * 2007-05-01 2017-10-04 University of Miami Transcriptomic biomarkers for individual risk assessment in new onset heart failure
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
WO2009100410A2 (en) * 2008-02-08 2009-08-13 Health Discovery Corporation Method and system for analysis of flow cytometry data using support vector machines
WO2010118782A1 (en) * 2009-04-17 2010-10-21 Universite Libre De Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
US20120142544A1 (en) 2009-06-02 2012-06-07 University Of Miami Diagnostic transcriptomic biomarkers in inflammatory cardiomyopathies
EP2553118B1 (en) 2010-03-31 2014-10-15 Sividon Diagnostics GmbH Method for breast cancer recurrence prediction under endocrine treatment
EP2589665A4 (en) 2010-06-29 2013-11-20 Univ Kurume Method for predicting therapeutic effect of immunotherapy on cancer patient, and gene set and kit to be used in the method
JP5854346B2 (en) * 2010-07-21 2016-02-09 公立大学法人秋田県立大学 Transcriptome analysis method, disease determination method, computer program, storage medium, and analysis apparatus
EP2686688B1 (en) 2011-03-17 2019-05-08 Cernostics, Inc. Systems and compositions for diagnosing barrett's esophagus and methods of using the same
EP2694963B1 (en) 2011-04-01 2017-08-02 Qiagen Gene expression signature for wnt/b-catenin signaling pathway and use thereof
US20140255954A1 (en) * 2011-10-24 2014-09-11 Atossa Genetics, Inc. Method of breast cancer detection
WO2014118333A1 (en) 2013-02-01 2014-08-07 Sividon Diagnostics Gmbh Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
US20150269355A1 (en) * 2014-03-19 2015-09-24 Peach Intellihealth, Inc. Managing allocation of health-related expertise and resources
CA3075265A1 (en) 2017-09-08 2019-03-14 Myriad Genetics, Inc. Method of using biomarkers and clinical variables for predicting chemotherapy benefit
WO2019104217A1 (en) * 2017-11-22 2019-05-31 The Trustees Of Columbia University In The City Of New York System method and computer-accessible medium for classifying breast tissue using a convolutional neural network

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRAMBILLA ET AL., BR. MED. J., vol. 1, no. 6013, April 1976 (1976-04-01), pages 801 - 804 *
MAGGARD ET AL., JOURNAL OF SURGICAL RESEARCH, vol. 113, 2003, pages 109 - 113 *
SORLIE T. ET AL.: "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PNAS, vol. 98, no. 19, 11 September 2001 (2001-09-11), pages 10869 - 10874, XP002215483 *

Also Published As

Publication number Publication date
EP1848825A2 (en) 2007-10-31
WO2006084272A2 (en) 2006-08-10
CA2596640A1 (en) 2006-08-10
WO2006084272A9 (en) 2007-10-04
JP2008536094A (en) 2008-09-04

Similar Documents

Publication Publication Date Title
WO2006084272A3 (en) Methods of predicting chemotherapy responsiveness in breast cancer patients
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2009050691A3 (en) Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2002055740A3 (en) Method for detecting disease associated mutations by means of primer extension
EP2367007A3 (en) Non-invasive in vitro method to detect transitional cell carcinoma of the bladder
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008060777A3 (en) Elisa for vegf
WO2006063042A3 (en) Selecting patients for therapy with a her inhibitor
EP2293074A3 (en) Method for diagnosing neuro-degenerative disease
WO2006133325A3 (en) Analysis of tissue samples surrounding malignancies
WO2001040517A3 (en) Evaluating and predicting clinical outcomes by gene expression analysis
EP2486924A3 (en) Drugs and uses
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2004055196A3 (en) Method for identifying risk of breast cancer and treatments thereof
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
WO2009039341A3 (en) Neoepitope detection of disease using protein arrays
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
WO2005005661A3 (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets
WO2004113574A3 (en) Methods for disease screening
WO2009091230A3 (en) Protein marker for breast-cancer monitoring, diagnosis and screening, and a breast-cancer monitoring, diagnosis and screening method using the same
WO2005062706A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
WO2002064097A3 (en) Vegf-d expression in brain cancer
WO2004040312A3 (en) Method for ngf assay for in vitro diagnosis of breast cancer and therapeutic use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2596640

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007554325

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006720440

Country of ref document: EP